Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma

被引：19

作者：

Castagna, Luca ^{[1
]}

Sarina, Barbara ^{[1
]}

Todisco, Elisabetta ^{[1
]}

Magagnoli, Massimo ^{[1
]}

Balzarotti, Monica ^{[1
]}

Bramanti, Stefania ^{[1
]}

Mazza, Rita ^{[1
]}

Anastasia, Antonella ^{[1
]}

Bacigalupo, Andrea ^{[2
]}

Aversa, Franco ^{[3
]}

Soligo, Davide ^{[4
]}

Giordano, Laura ^{[5
]}

Santoro, Armando ^{[1
]}

机构：

[1] Ist Clin Humanitas, Dept Hematol Oncol, I-20089 Milan, Italy

[2] Osped San Martino Genova, Hematol Div 2, Genoa, Italy

[3] Univ Perugia, Dept Clin & Expt Med, HSCT Unit, Hematol Sect, I-06100 Perugia, Italy

[4] Univ Milan, Osped Maggiore Policlin, Bone Marrow Unit, Dept Hematol Oncol, Milan, Italy

[5] Ist Clin Humanitas, Stat Unit, Milan, Italy

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2009年 / 15卷 / 04期

关键词：

Hodgkin lymphoma; High-dose chemotherapy; Salvage chemotherapy; Allogeneic transplantation; HIGH-DOSE CHEMOTHERAPY; PROGRESSIVE DISEASE; MARROW TRANSPLANTATION; AUTOLOGOUS TRANSPLANT; PROGNOSTIC-FACTORS; CLINICAL-COURSE; EUROPEAN GROUP; WORKING PARTY; INTENSITY; MANAGEMENT;

D O I：

10.1016/j.bbmt.2008.12.506

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HID.

引用

页码：432 / 438

页数：7

共 38 条

[1] Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].

Alvarez, I ;

Sureda, A ;

Caballero, MD ;

Urbano-Ispizzua, A ;

Ribera, JM ;

Canales, M ;

García-Conde, J ;

Sanz, G ;

Arranz, R ;

Bernal, MT ;

de la Serna, J ;

Díez, JL ;

Moraleda, JM ;

Rubió-Félix, D ;

Xicoy, B ;

Martínez, C ;

Mateos, MV ;

Sierra, J .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183

[2] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen [J].

Anderlini, P ;

Saliba, R ;

Acholonu, S ;

Okoroji, GJ ;

Donato, M ;

Giralt, S ;

Andersson, B ;

Ueno, NT ;

Khouri, I ;

De Lima, M ;

Hosing, C ;

Cohen, A ;

Ippoliti, C ;

Romaguera, J ;

Rodriguez, MA ;

Pro, B ;

Fayad, L ;

Goy, A ;

Younes, A ;

Champlin, RE .

BONE MARROW TRANSPLANTATION, 2005, 35 (10) :943-951

[3] Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience [J].

Anderlini, Paolo ;

Saliba, Rima ;

Acholonu, Sandra ;

Giralt, Sergio A. ;

Andersson, Borje ;

Ueno, Naoto T. ;

Hosing, Chitra ;

Khouri, Issa F. ;

Couriel, Daniel ;

de Lima, Marcos ;

Qazilbash, Muzaffar H. ;

Pro, Barbara ;

Romaguera, Jorge ;

Fayad, Luis ;

Hagemeister, Frederick ;

Younes, Anas ;

Munsell, Mark F. ;

Champlin, Richard E. .

HAEMATOLOGICA, 2008, 93 (02) :257-264

[4] ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].

ANDERSON, JE ;

LITZOW, MR ;

APPELBAUM, FR ;

SCHOCH, G ;

FISHER, LD ;

BUCKNER, CD ;

PETERSEN, FB ;

CRAWFORD, SW ;

PRESS, OW ;

SANDERS, JE ;

BENSINGER, WI ;

MARTIN, PJ ;

STORB, R ;

SULLIVAN, KM ;

HANSEN, JA ;

THOMAS, ED .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350

[5] Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens [J].

Ardeshna, KM ;

Kakouros, N ;

Qian, W ;

Powell, MG ;

Saini, N ;

D'Sa, S ;

Mackinnon, S ;

Hoskin, PJ ;

Goldstone, AH ;

Linch, DC .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) :363-372

[6] Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse [J].

Aversa, F ;

Terenzi, A ;

Tabilio, A ;

Falzetti, F ;

Carotti, A ;

Ballanti, S ;

Felicini, R ;

Falcinelli, F ;

Velardi, A ;

Ruggeri, L ;

Aloisi, T ;

Saab, JP ;

Santucci, A ;

Perruccio, K ;

Martelli, MP ;

Mecucci, C ;

Reisner, Y ;

Martelli, MF .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3447-3454

[7] Progressive disease after ABMT for Hodgkin's disease [J].

Bolwell, BJ ;

Kalaycio, M ;

Goormastic, M ;

Dannley, R ;

Andresen, SW ;

Lichtin, A ;

Overmoyer, B ;

Pohlman, B .

BONE MARROW TRANSPLANTATION, 1997, 20 (09) :761-765

[8] Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry [J].

Brice, P ;

Bouabdallah, R ;

Moreau, P ;

Divine, M ;

Andre, M ;

Aoudjane, M ;

Fleury, J ;

Anglaret, B ;

Baruchel, A ;

Sensebe, L ;

Colombat, P .

BONE MARROW TRANSPLANTATION, 1997, 20 (01) :21-26

[9] Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study [J].

Castagna, Luca ;

Magagnoli, Massimo ;

Balzarotti, Monica ;

Sarina, Barbara ;

Siracusano, Licia ;

Nozza, Andrea ;

Todisco, Elisabetta ;

Bramanti, Stefania ;

Mazza, Rita ;

Russo, Filippo ;

Timofeeva, Inna ;

Santoro, Armando .

AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (02) :122-127

[10] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

← 1 2 3 4 →